Mutations in the fks1 gene in Candida albicans, C-tropicalis, and C-krusei correlate with elevated caspofungin MICs uncovered in AM3 medium using the method of the European Committee on Antibiotic Susceptibility Testing

被引:102
作者
Desnos-Ollivier, Marie [1 ]
Bretagne, Stephane [1 ]
Raoux, Dorothee [1 ]
Hoinard, Damien [1 ]
Dromer, Francoise [1 ]
Dannaoui, Eric [1 ,2 ]
机构
[1] Inst Pasteur, CNRS URA 3012, Unite Mycol Mol, Ctr Natl Reference Mycol & Antifong, F-75724 Paris 15, France
[2] Univ Paris 05, Fac Med, Unite Parasitol Mycol, Hop Europeen Georges Pompidou,AP HP, F-75015 Paris, France
关键词
D O I
10.1128/AAC.00088-08
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Mutations in two specific regions of the Fks1 subunit of 1,3-beta-D-glucan synthase are known to confer decreased caspofungin susceptibility on Candida spp. Clinical isolates of Candida spp. (404 Candida albicans, 62 C. tropicalis, and 21 C. krusei isolates) sent to the French National Reference Center were prospectively screened for susceptibility to caspofungin in vitro by the broth microdilution reference method of the Antifungal Susceptibility Testing Subcommittee of the European Committee on Antibiotic Susceptibility Testing (AFST-EUCAST). Twenty-eight isolates (25 C. albicans, 2 C. tropicalis, and 1 C. krusei isolate) for which the caspofungin MIC was above the MIC that inhibited 90% of the isolates of the corresponding species (MIC90) were subjected to molecular analysis in order to identify mutations in the fks1 gene. Substitutions in the deduced protein sequence of Fks1 were found for 8 isolates, and 20 isolates had the wild-type sequence. Among the six C. albicans isolates harboring mutations, six patterns were observed involving amino acid changes at positions 641, 645, 649, and 1358. For C. tropicalis, one isolate showed an L644W mutation, and for one C. krusei isolate, two mutations, L658W and L701M, were found. Two media, RPMI medium and AM3, were tested for their abilities to distinguish between isolates with wild- type Fks1 and those with mutant Fks1. In RPMI medium, caspofungin MICs ranged from 0.25 to 2 mu g/ml for wild- type isolates and from 1 to 8 mu g/ml for mutant isolates. A sharper difference was observed in AM3: all wild-type isolates were inhibited by 0.25 mu g/ml of caspofungin, while caspofungin MICs for all mutant isolates were >= 0.5 mu g/ml. These data demonstrate that clinical isolates of C. albicans, C. tropicalis, and C. krusei with decreased susceptibility to caspofungin in vitro have diverse mutations in the fks1 gene and that AM3 is potentially a better medium than RPMI for distinguishing between mutant and wild- type isolates using the AFST-EUCAST method.
引用
收藏
页码:3092 / 3098
页数:7
相关论文
共 32 条
  • [1] [Anonymous], CLIN MICROBIOL INFEC
  • [2] [Anonymous], CLIN MICROBIOL INFEC
  • [3] Acquired resistance to echinocandins in Candida albicans:: case report and review
    Baixench, Marie-Therese
    Aoun, Naji
    Desnos-Ollivier, Marie
    Garcia-Hermoso, Dea
    Bretagne, Stephane
    Ramires, Sandrine
    Piketty, Christophe
    Dannaoui, Eric
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2007, 59 (06) : 1076 - 1083
  • [4] Assessing resistance to the echinocandin antifungal drug caspofungin in Candida albicans by profiling mutations in FKS1
    Balashov, Sergey V.
    Park, Steven
    Perlin, David S.
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2006, 50 (06) : 2058 - 2063
  • [5] Influences of methodological variables on susceptibility testing of caspofungin against Candida species and Aspergillus fumigatus
    Bartizal, C
    Odds, FC
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (07) : 2100 - 2107
  • [6] Comparison of the Antifungal Susceptibility Testing Subcommittee of the European Committee on Antibiotic Susceptibility Testing proposed standard and the E-test with the NCCLS broth microdilution method for voriconazole and caspofungin susceptibility testing of yeast species
    Chryssanthou, E
    Cuenca-Estrella, M
    [J]. JOURNAL OF CLINICAL MICROBIOLOGY, 2002, 40 (10) : 3841 - 3844
  • [7] Head-to-head comparison of the activities of currently available antifungal agents against 3,378 Spanish clinical isolates of yeasts and filamentous fungi
    Cuenca-Estrella, M
    Gomez-Lopez, A
    Mellado, E
    Buitrago, MJ
    Monzon, A
    Rodriguez-Tudela, JL
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2006, 50 (03) : 917 - 921
  • [8] In vitro susceptibilities of bloodstream isolates of Candida species to six antifungal agents:: results from a population-based active surveillance programme, Barcelona, Spain, 2002-2003
    Cuenca-Estrella, M
    Rodriguez, D
    Almirante, B
    Morgan, J
    Planes, AM
    Almela, M
    Mensa, J
    Sanchez, F
    Ayats, J
    Gimenez, M
    Salvado, M
    Warnock, DW
    Pahissa, A
    Rodriguez-Tudela, JL
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2005, 55 (02) : 194 - 199
  • [9] Comparative in vitro activities of caspofungin and micafungin, determined using the method of the European Committee on Antimicrobial Susceptibility Testing, against yeast isolates obtained in France in 2005-2006
    Dannaoui, E.
    Lortholary, O.
    Raoux, D.
    Bougnoux, M. E.
    Galeazzi, G.
    Lawrence, C.
    Moissenet, D.
    Poilane, I.
    Hoinard, D.
    Dromer, F.
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2008, 52 (02) : 778 - 781
  • [10] Echinocandin antifungal drugs
    Denning, DW
    [J]. LANCET, 2003, 362 (9390) : 1142 - 1151